ADPKD with Polycystic Liver Disease: Next Step When Somatostatin Analogues Have Not Worked
In ADPKD, markedly enlarged polycystic liver disease causing severe volume-related symptoms requires stepwise management. When the initial treatment strategy does not achieve sufficient control, a defined escalation protocol applies.
Clinical Scenario
ADPKD complicated by markedly enlarged polycystic liver disease with severe volume-related symptoms. The hepatic burden in this population drives significant morbidity and determines the treatment pathway.
Previous Treatment — Inadequate Response
Long-acting somatostatin analogues (lanreotide or octreotide) were used with the goals of reducing symptom burden and decreasing polycystic liver volume. After 6–12 months of treatment, these goals were not adequately achieved — neither sufficient symptom relief nor meaningful volume reduction was attained. This failure of response triggers escalation to the next management step.
Next-Step Approach
When prior medical therapy has not provided adequate relief and the liver disease has reached a massive extent, the management approach involves referral for a major intervention — the full criteria, conditions, and pathway are set out in the structured protocol.
References
DOI: 10.1016/j.kint.2024.07.010
We recommend prescribing long-acting somatostatin analogues in people with ADPKD and markedly enlarged polycystic livers with severe volume-related symptoms (1B).
People with PLD should be referred for liver transplantation in the event of massive PLD in the absence of contraindications or alternative treatment options.
View source ↗